Neuroinflammation in the peripheral nerve: Cause, modulator, or bystander in peripheral neuropathies?

GLIA

Volumn 64, Issue 4, 2016, Pages 475-486

  Martini, Rudolf ^a   Willison, Hugh ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adaptive immune system; Fibroblast; Innate immune system; Lymphocytes; Macrophage; Nodes of Ranvier

Indexed keywords

ANTIGEN;

ARTICLE; CHRONIC DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DIABETIC NEUROPATHY; FAMILIAL AMYLOID POLYNEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; PERIPHERAL NERVE INFLAMMATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; PERIPHERAL NERVE; PHYSIOLOGY;

ANIMALS; HUMANS; NEUROIMMUNOMODULATION; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84958751821     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22899     Document Type: Article

References (104)

1. Adams D, Theaudin M, Cauquil C, Algalarrondo V, Slama M. 2014. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep 14:435
2. Andratsch M, Mair N, Constantin CE, Scherbakov N, Benetti C, Quarta S, Vogl C, Sailer CA, Uceyler N, Brockhaus J, et al. 2009. A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci 29:13473-13483.
3. Anzini P, Neuberg DHH, Schachner M, Nelles E, Willecke K, Zielasek J, Toyka KV, Suter U, Martini R. 1997. Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J Neurosci 17:4545-4551.
4. Bekircan-Kurt CE, Uceyler N, Sommer C. 2014. Cutaneous activation of rage in nonsystemic vasculitic and diabetic neuropathy. Muscle Nerve 50:377-383.
5. Beppu M, Sawai S, Misawa S, Sogawa K, Mori M, Ishige T, Satoh M, Nomura F, Kuwabara S. 2015. Serum cytokine and chemokine profiles in patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 279:7-10.
6. Berger P, Niemann A, Suter U. 2006. Schwann cells and the pathogenesis of inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia 54:243-257.
7. Boyle ME, Berglund EO, Murai KK, Weber L, Peles E, Ranscht B. 2001. Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve. Neuron 30:385-397.
8. Campana WM, Li X, Shubayev VI, Angert M, Cai K, Myers RR. 2006. Erythropoietin reduces Schwann cell TNF-alpha, Wallerian degeneration and pain-related behaviors after peripheral nerve injury. Eur J Neurosci 23:617-626.
9. Carenini S, Maurer M, Werner A, Blazyca H, Toyka KV, Schmid CD, Raivich G, Martini R. 2001. The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J Cell Biol 152:301-308.
10. Cashman CR, Hoke A. 2015. Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci Lett 596:33-50.
11. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. 1997. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 745:32-36.
12. Chitu V, Stanley ER. 2006. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 18:39-48.
13. Cocito D, Romagnolo A, Rosso M, Peci E, Lopiano L, Merola A. 2015. CIDP-like neuropathies in graft versus host disease. J Peripher Nerv Syst 20:1-6.
14. Crawford TO, Griffin JW. 1991. Morphometrical and ultrastructural evaluation of the sural nerve in children with Charcot-Marie-Tooth: Implication for pathogenesis and treatment. Ann Neurol 30:500.
15. Doppler K, Appeltshauser L, Wilhelmi K, Villmann C, Dib-Hajj SD, Waxman SG, Maurer M, Weishaupt A, Sommer C. 2015. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 86:720-728.
16. Dyck PJ, Giannini C. 1996. Pathologic alterations in the diabetic neuropathies of humans: A review. J Neuropathol Exp Neurol 55:1181-1193.
17. Dyck PJ, Windebank AJ. 2002. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: New insights into pathophysiology and treatment. Muscle Nerve 25:477-491.
18. Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, et al. 2014. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82:380-397.
19. Fischer S, Kleinschnitz C, Müller M, Kobsar I, Ip CW, Rollins BJ, Martini R. 2008a. Monocyte chemoattractant protein-1 is a pathogenic component in a model for a hereditary peripheral neuropathy. Mol Cell Neurosci 37:359-366.
20. Fischer S, Weishaupt A, Troppmair J, Martini R. 2008b. Increase of MCP-1 (CCL2) in myelin mutant Schwann cells is mediated by MEK-ERK signaling pathway. Glia 56:836-843.
21. Fledrich R, Stassart RM, Klink A, Rasch LM, Prukop T, Haag L, Czesnik D, Kungl T, Abdelaal TA, Keric N, et al. 2014. Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med 20:1055-1061.
22. Fledrich R, Stassart RM, Sereda MW. 2012. Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease. Br Med Bull 102:89-113.
23. Gao YJ, Ji RR. 2010. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 126:56-68.
24. Giese KP, Martini R, Lemke G, Soriano P, Schachner M. 1992. Mouse P0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71:565-576.
25. Gold R, Hartung HP, Toyka KV. 2000. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 6:88-91.
26. Goncalves NP, Teixeira-Coelho M, Saraiva MJ. 2015. Protective role of anakinra against transthyretin-mediated axonal loss and cell death in a mouse model of familial amyloidotic polyneuropathy. J Neuropathol Exp Neurol 74:203-217.
27. Goncalves NP, Vieira P, Saraiva MJ. 2014. Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis. Amyloid 21:175-184.
28. Griffin JW, Li CY, Macko C, Ho TW, Hsieh ST, Xue P, Wang FA, Cornblath DR, McKhann GM, Asbury AK. 1996. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barre syndrome. J Neurocytol 25:33-51.
29. Groh J, Heinl K, Kohl B, Wessig C, Greeske J, Fischer S, Martini R. 2010. Attenuation of MCP-1/CCL2 expression ameliorates neuropathy in a mouse model for Charcot-Marie-Tooth 1X. Hum Mol Genet 19:3530-3543.
30. Groh J, Klein I, Hollmann C, Wettmarshausen J, Klein D, Martini R. 2015a. CSF-1-activated macrophages are target-directed and essential mediators of Schwann cell dedifferentiation and dysfunction in Cx32-deficient mice. Glia 63:977-986.
31. Groh J, Klein D, Kroner A, Martini R. 2015b. Inflammation in the pathogenesis of inherited peripheral neuropathies. In: David S, editor. Neuroinflammation: New Insights into Beneficial and Detrimental Functions. Wiley, Hoboken, New Jersey, pp 123-137.
32. Groh J, Weis J, Zieger H, Stanley ER, Heuer H, Martini R. 2012. Colony-stimulating factor-1 mediates macrophage-related neural damage in a model for Charcot-Marie-Tooth disease type 1X. Brain 135:88-104.
33. Hafer-Macko C, Hsieh ST, Li CY, Ho TW, Sheikh K, Cornblath DR, McKhann GM, Asbury AK, Griffin JW. 1996. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma. Ann Neurol 40:635-644.
34. Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC. 2004. The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 23:3061-3071.
35. Ho TW, Willison HJ, Nachamkin I, Li CY, Veitch J, Ung H, Wang GR, Liu RC, Cornblath DR, Asbury AK, Griffin JW, McKhann GM. 1999. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol 45:168-173.
36. Hoke A. 2012. Animal models of peripheral neuropathies. Neurotherapeutics 9:262-269.
37. Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Sabéran-Djoniedi D, Figarella-Branger D, Pellisier JF, Thomas PK, Fontes M. 1998. Correlation between varying levels and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 7:449-458.
38. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. 1995. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 38:218-224.
39. Jerath NU, Shy ME. 2014. Hereditary motor and sensory neuropathies: Understanding molecular pathogenesis could lead to future treatment strategies. Biochim Biophys Acta 1852:667-678.
40. Juranek JK, Geddis MS, Rosario R, Schmidt AM. 2013. Impaired slow axonal transport in diabetic peripheral nerve is independent of RAGE. Eur J Neurosci 38:3159-3168.
41. Klehmet J, Goehler J, Ulm L, Kohler S, Meisel C, Meisel A, Harms H. 2015. Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP. J Neurol Neurosurg Psychiatry 86:686-691.
42. Klein D, Groh J, Wettmarshausen J, Martini R. 2014. Nonuniform molecular features of myelinating Schwann cells in models for CMT1: Distinct disease patterns are associated with NCAM and c-Jun upregulation. Glia 62:736-750.
43. Klein D, Groh J, Weishaupt A, Martini R. 2015a. Endogenous antibodies contribute to macrophage-mediated demyelination in a mouse model for CMT1B. J Neuroinflammation 12:49
44. Klein D, Patzkó Á, Schreiber D, van Hauwermeiren A, Baier M, Groh J, West BL, Martini R. In press. Targeting the Colony-Stimulating Factor-1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice. Brain.
45. Kobsar I, Berghoff M, Samsam M, Wessig C, Maurer M, Toyka KV, Martini R. 2003. Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice lacking the recombination activating gene-1. Brain 126:804-813.
46. Kohl B, Fischer S, Groh J, Wessig C, Martini R. 2010a. MCP-1/CCL2 modifies axon properties in a PMP22-overexpressing mouse model for Charcot-Marie-Tooth 1A neuropathy. Am J Pathol 176:1390-1399.
47. Kohl B, Groh J, Wessig C, Wiendl H, Kroner A, Martini R. 2010b. Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A. Neurobiol Dis 38:78-84.
48. Kusunoki S, Hitoshi S, Kaida K, Murayama S, Kanazawa I. 1999. Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum. Neurosci Lett 273:33-36.
49. Labasque M, Hivert B, Nogales-Gadea G, Querol L, Illa I, Faivre-Sarrailh C. 2014. Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem 289:7907-7918.
50. Lim JP, Devaux J, Yuki N. 2014. Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. Autoimmun Rev 13:1070-1078.
51. Lin L, Park S, Lakatta EG. 2009. RAGE signaling in inflammation and arterial aging. Front Biosci 14:1403-1413.
52. Liu J, Wang LN, McNicol ED. 2015. Pharmacological treatment for pain in Guillain-Barre syndrome. Cochrane Database Syst Rev 4:CD009950
53. Liu JX, Willison HJ, Pedrosa-Domellof F. 2009. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Investig Ophthalmol Vis Sci 50:3226-3232.
54. Mantovani A, Sica A. 2010. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 22:231-237.
55. Martini R. 2014. Neuregulin-1 alleviates Charcot-Marie-Tooth disease in rats. Nat Med 20:984-985.
56. Martini R, Klein D, Groh J. 2013. Similarities between inherited demyelinating neuropathies and Wallerian degeneration: An old repair program may cause myelin and axon perturbation under nonlesion conditions. Am J Pathol 183:655-660.
57. Martini R, Zielasek J, Toyka KV, Giese KP, Schachner M. 1995. Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat Genet 11:281-286.
58. Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, Taylor BV, Dyck PJ, Kiernan MC, Lin CS. 2015. Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype. J Neurol Neurosurg Psychiatry
59. Maurer M, Toyka KV, Gold R. 2002. Cellular immunity in inflammatory autoimmune neuropathies. Revue Neurol 158:S7-S15.
60. Meeusen JW, Klein CJ, Pirko I, Haselkorn KE, Kryzer TJ, Pittock SJ, Lachance DH, Dyck PJ, Lennon VA. 2012. Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. Ann Neurol 71:417-426.
61. Melzer N, Meuth SG. 2014. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: Common and divergent current and future strategies. Clin Exp Immunol 175:359-372.
62. Meyer zu Horste G, Cordes S, Mausberg AK, Zozulya AL, Wessig C, Sparwasser T, Mathys C, Wiendl H, Hartung HP, Kieseier BC. 2014. FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies. PLoS One 9:e108756
63. Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, Wong AH, Yuki N, Group CCS. 2015. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138:1484-1491.
64. Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimaraes A, Saraiva MJ. 2006. Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 97:151-161.
65. Napoli I, Noon LA, Ribeiro S, Kerai AP, Parrinello S, Rosenberg LH, Collins MJ, Harrisingh MC, White IJ, Woodhoo A, Lloyd AC. 2012. A central role for the ERK-signaling pathway in controlling Schwann cell plasticity and peripheral nerve regeneration in vivo. Neuron 73:729-742.
66. Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, Linington C, Odaka M, Tackenberg B, Pruss H, Schwab JM, Harms L, Harms H, Sommer C, Rasband MN, Eshed-Eisenbach Y, Peles E, Hohlfeld R, Yuki N, Dornmair K, Meinl E. 2012. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79:2241-2248.
67. Nobile-Orazio E, Gallia F. 2013. Multifocal motor neuropathy: Current therapies and novel strategies. Drugs 73:397-406.
68. Nolano M, Manganelli F, Provitera V, Pisciotta C, Stancanelli A, Caporaso G, Iodice R, Shy ME, Santoro L. 2015. Small nerve fiber involvement in CMT1A. Neurology 84:407-414.
69. Odaka M, Yuki N, Nobile-Orazio E, Carpo M, Hirata K. 2000. Antibodies to GM1(NeuGc) in Guillain-Barre syndrome after ganglioside therapy. J Neurol Sci 175:96-106.
70. Orita S, Henry K, Mantuano E, Yamauchi K, De Corato A, Ishikawa T, Feltri ML, Wrabetz L, Gaultier A, Pollack M, Ellisman M, Takahashi K, Gonias SL, Campana WM. 2013. Schwann cell LRP1 regulates remak bundle ultrastructure and axonal interactions to prevent neuropathic pain. J Neurosci 33:5590-5602.
71. Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, Suarez-Calvet X, Navas M, Araque J, Gallardo E, Illa I. 2013. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 73:370-380.
72. Rusconi P, Caiola E, Broggini M. 2012. RAS/RAF/MEK inhibitors in oncology. Curr Med Chem 19:1164-1176.
73. Sandireddy R, Yerra VG, Areti A, Komirishetty P, Kumar A. 2014. Neuroinflammation and oxidative stress in diabetic neuropathy: Futuristic strategies based on these targets. Int J Endocrinol 2014:674987
74. Schmid CD, Stienekemeier M, Oehen S, Bootz F, Zielasek J, Gold R, Toyka KV, Schachner M, Martini R. 2000. Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance. JNeurosci 20:729-735.
75. Scott LJ. 2014. Tafamidis: A review of its use in familial amyloid polyneuropathy. Drugs 74:1371-1378.
76. Sekijima Y. 2014. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharmacy Therapeut 39:225-233.
77. Shi X, Chen Y, Nadeem L, Xu G. 2013. Beneficial effect of TNF-alpha inhibition on diabetic peripheral neuropathy. J Neuroinflammation 10:69
78. Soliven B. 2011. Immune mechanisms in spontaneously occurring CIDP in NOD mice. J Peripher Nerv Syst 16 Suppl 1:56-59.
79. Soliven B. 2014. Animal models of autoimmune neuropathy. Ilar J 54:282-290.
80. Sommer C. 2008. Skin biopsy as a diagnostic tool. Curr Opin Neurol 21:563-568.
81. Sorkin LS, Xiao WH, Wagner R, Myers RR. 1997. Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81:255-262.
82. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ. 2001a. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: Evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159:1993-2000.
83. Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D. Saraiva MJ, 2001b. Familial amyloid polyneuropathy: Receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 21:7576-7586.
84. Stoll G, Gabreels-Festen AA, Jander S, Muller HW, Hanemann CO. 1998. Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type 1 and hereditary neuropathy with liability to pressure palsies. Muscle Nerve 21:1419-1427.
85. Suter U, Snipes GJ. 1995. Biology and genetics of hereditary motor and sensory neuropathies. Annu Rev Neurosci 18:45-75.
86. Takada K, Shimizu J, Kusunoki S. 2008. Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp Neurol 209:279-283.
87. Timmerman V, Strickland AV, Zuchner S. 2014. Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the human genome project success. Genes 5:13-32.
88. Tracy JA, Dyck PJ. 2011. Auto-immune polyradiculoneuropathy and a novel IgG biomarker in workers exposed to aerosolized porcine brain. J Peripher Nerv Syst 16 Suppl 1:34-7.
89. Uceyler N, Sommer C. 2008. Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett 437:194-198.
90. Ueda M, Ando Y. 2014. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener 3:19
91. Uncini A, Kuwabara S. 2015. Nodopathies of the peripheral nerve: An emerging concept. J Neurol Neurosurg Psychiatry.
92. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. 2014. Guillain-Barre syndrome: Pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10:469-482.
93. Vargas ME, Watanabe J, Singh SJ, Robinson WH, Barres BA. 2010. Endogenous antibodies promote rapid myelin clearance and effective axon regeneration after nerve injury. Proc Natl Acad Sci USA 107:11993-11998.
94. Vincent AM, Callaghan BC, Smith AL, Feldman EL. 2011. Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nat Rev Neurol 7:573-583.
95. Walters ET. 2014. Neuroinflammatory contributions to pain after SCI: Roles for central glial mechanisms and nociceptor-mediated host defense. Exp Neurol 258:48-61.
96. Willison HJ. 2014. Glycoconjugates and neuroimmunological diseases. Adv Neurobiol 9:543-566.
97. Willison HJ, Goodyear CS. 2013. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol 34:453-459.
98. Willison HJ, Yuki N. 2002. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591-2625.
99. Yagita M, Hamano T, Hatachi S, Fujita M. 2013. Peripheral neuropathies during biologic therapies. Mod Rheumatol. doi:10.3109/14397595.2013.859770
100. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D. 1994. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897.
101. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. 2000. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6:643-651.
102. Yeh CH, Sturgis L, Haidacher J, Zhang XN, Sherwood SJ, Bjercke RJ, Juhasz O, Crow MT, Tilton RG, Denner L. 2001. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50:1495-1504.
103. Yuki N, Uncini A. 2014. Acute and chronic ataxic neuropathies with disialosyl antibodies: A continuous clinical spectrum and a common pathophysiological mechanism. Muscle Nerve 49:629-635.
104. Yuki N, Yoshino H, Sato S, Miyatake T. 1990. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40:1900-1902.